bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Tables 1 - 6 from Association of Interleukin-28B Genotype and Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
Authors: Hodo Yuji , Honda Masao , Tanaka Akihiro , Nomura Yoshimoto , Arai Kuniaki , Yamashita Taro , Sakai Yoshio , Yamashita Tatsuya , Mizukoshi Eishiro , Sakai Akito , Sasaki Motoko , Nakanuma Yasuni , Moriyama Mitsuhiko , Kaneko Shuichi
Published: April 2023

PDF file - 200K, Table S1. Clinical features of 20 HCC patients for Affymetrix genechip analysis; Table S2. The list of Probe ID of genes for hierarchical clustering; Table S3. Differentially expressed gene sets classified with Gene Ontology in HCC tissues of IL28B TG/GG genotype (p < 0.001); Table S4. Comparison of tumor infiltrate lymphocyte between IL28B TT and TG/GG genotypes; Table S5. Cox regression analysis and relative frequency of variables inclusion with p-value <0.05 (in 1000 bootstrap samples) for early HCC recurrence (≤1year); Table S6. Cox regression analysis and relative frequency of variables inclusion with p-value <0.05 (in 1000 bootstrap samples) for late HCC recurrence (1year<).
Supplementary Figure Legends from Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome
Authors: Karlsson Anna , Jönsson Mats , Lauss Martin , Brunnström Hans , Jönsson Per , Borg Åke , Jönsson Göran , Ringnér Markus , Planck Maria , Staaf Johan
Published: April 2023

Supplementary Figure Legends. Document containing figure legends for supplementary figures.
Supplementary Figure Legend from Association of Interleukin-28B Genotype and Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
Authors: Hodo Yuji , Honda Masao , Tanaka Akihiro , Nomura Yoshimoto , Arai Kuniaki , Yamashita Taro , Sakai Yoshio , Yamashita Tatsuya , Mizukoshi Eishiro , Sakai Akito , Sasaki Motoko , Nakanuma Yasuni , Moriyama Mitsuhiko , Kaneko Shuichi
Published: April 2023

PDF file - 72K
Supplemental figure 5 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Authors: Wardell Suzanne E. , Ellis Matthew J. , Alley Holly M. , Eisele Koleen , VanArsdale Todd , Dann Stephen G. , Arndt Kim T. , Primeau Tina , Griffin Elizabeth , Shao Jieya , Crowder Robert , Lai Jin-Ping , Norris John D. , McDonnell Donald P. , Li Shunqiang
Published: April 2023

Supplemental figure 5: IHC analysis of treated PDX tumors indicated on-target activity of bazedoxifene and palbociclib
Supplementary figure 5 from Intratumor Heterogeneity in Hepatocellular Carcinoma
Authors: Friemel Juliane , Rechsteiner Markus , Frick Lukas , Böhm Friederike , Struckmann Kirsten , Egger Michèle , Moch Holger , Heikenwalder Mathias , Weber Achim
Published: April 2023

Supplementary figure 5. Staining intensities AFP, CD44 and EpCam
Supplementary Table Legend from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
Authors: Zheng Hong , Zhao Weipeng , Yan Cihui , Watson Crystina C. , Massengill Michael , Xie Mengyu , Massengill Chris , Noyes David R. , Martinez Gary V. , Afzal Roha , Chen Zhihua , Ren Xiubao , Antonia Scott J. , Haura Eric B. , Ruffell Brian , Beg Amer A.
Published: April 2023

Supplementary Table Legend
Data Supplement from Demethylating Drugs as Novel Analgesics for Cancer Pain
Authors: Viet Chi T. , Dang Dongmin , Ye Yi , Ono Kentaro , Campbell Ronald R. , Schmidt Brian L.
Published: April 2023

Supplementary Figure S3. (A and B) The graphs compare beta-endorphin levels in the supernatant of oral SCC (HSC-3) cells re-expressing mu-opioid receptor and control oral SCC cells, with and without naloxone treatment. Cells transduced with Ad-OPRM1 at 200 MOI secreted an average of 400pg/ml beta-endorphin, which was significantly higher than non-transduced cells (*p < 0.05, One-way ANOVA, Holm-Sidak test). When treated with naloxone (10-6 to 10-12 mol/L) Ad-OPRM1 HSC-3 cells secreted significantly less beta-endorphin than the control vehicle-treated Ad-OPRM1 HSC-3 cells at all naloxone concentrations (p<0.01, One-way ANOVA, Holm-Sidak test). (C) Combination treatment resulted in significantly higher secretion of beta-endorphin than single treatment or control vehicle (***p<.001, One-way ANOVA, Holm-Sidak test).
Supplementary figure 2 from WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy
Authors: Bosch Linda J.W. , Luo Yanxin , Lao Victoria V. , Snaebjornsson Petur , Trooskens Geert , Vlassenbroeck Ilse , Mongera Sandra , Tang Weiliang , Welcsh Piri , Herman James G. , Koopman Miriam , Nagtegaal Iris D. , Punt Cornelis J.A. , van Criekinge Wim , Meijer Gerrit A. , Monnat Raymond J. , Carvalho Beatriz , Grady William M.
Published: April 2023

Progression Free survival in metastatic CRC patients with unmethylated or methylated WRN promoter regions, in response to second line irinotecan (IRI) treatment in the sequential treatment arm (arm A).
Supplementary Table 2 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
Authors: Hagleitner Melanie M. , Coenen Marieke J.H. , Gelderblom Hans , Makkinje Remco R. , Vos Hanneke I. , de Bont Eveline S.J.M. , van der Graaf Winette T.A. , Schreuder H.W. Bart , Flucke Uta , van Leeuwen Frank N. , Hoogerbrugge Peter M. , Guchelaar Henk-Jan , te Loo Dunja M.W.M
Published: April 2023

Supplementary Table 2. Genetic variants associated with histologic response
Supplementary Figure Legend from Differential Expression of 2′,3′-Cyclic-Nucleotide 3′-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient Survival
Authors: Zorniak Michael , Clark Paul A. , Leeper Heather E. , Tipping Matthew D. , Francis David M. , Kozak Kevin R. , Salamat M. Shahriar , Kuo John S.
Published: April 2023

PDF file, 91KB.
Figure S1 from Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
Authors: Whatcott Clifford J. , Diep Caroline H. , Jiang Ping , Watanabe Aprill , LoBello Janine , Sima Chao , Hostetter Galen , Shepard H. Michael , Von Hoff Daniel D. , Han Haiyong
Published: April 2023

Figure S1. Kaplan-Meier survival curves for patients with high and low levels of α-SMA, Collagen III (Col III), and Collagen IV (Col IV), and differing histological grades in their primary tumors.
Supplementary Table 2 from Targeting Cancer Cells via the Reactive Oxygen Species-Mediated Unfolded Protein Response with a Novel Synthetic Polyphenol Conjugate
Authors: Shin Soon Young , Lee Jong Min , Lee Mi So , Koh Dongsoo , Jung Hyeryoung , Lim Yoongho , Lee Young Han
Published: April 2023

PDF file - 54K, Residuals between experimental data and values predicted using CoMFA for polyphenols.
Supplementary Table 1 from Targeting Cancer Cells via the Reactive Oxygen Species-Mediated Unfolded Protein Response with a Novel Synthetic Polyphenol Conjugate
Authors: Shin Soon Young , Lee Jong Min , Lee Mi So , Koh Dongsoo , Jung Hyeryoung , Lim Yoongho , Lee Young Han
Published: April 2023

PDF file - 238K, Structures of polyphenols used for CoMFA and their biological activities.
Supplementary Figure 2 from Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
Authors: Wulfkuhle Julia D. , Berg Daniela , Wolff Claudia , Langer Rupert , Tran Kai , Illi Julie , Espina Virginia , Pierobon Mariaelena , Deng Jianghong , DeMichele Angela , Walch Axel , Bronger Holger , Becker Ingrid , Waldhör Christine , Höfler Heinz , Esserman Laura , Liotta Lance A. , Becker Karl-Friedrich , Petricoin Emanuel F.
Published: April 2023

PDF file - 103K, Validation of the reproducibility of the RPMA for HER2 and pHER2 analysis from FFPE-tissues
Supplementary Figure 2A from Blocking and Randomization to Improve Molecular Biomarker Discovery
Authors: Qin Li-Xuan , Zhou Qin , Bogomolniy Faina , Villafania Liliana , Olvera Narciso , Cavatore Magali , Satagopan Jaya M. , Begg Colin B. , Levine Douglas A.
Published: April 2023

PDF file - 25KB, Boxplot of TPR and FPR from the simulation study examining various experimental designs of array-to-sample assignment: (a) before normalization.
Supplementary Figure 1 from Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors
Authors: Guerra Emanuela , Trerotola Marco , Tripaldi Romina , Aloisi Anna Laura , Simeone Pasquale , Sacchetti Andrea , Relli Valeria , D'Amore Antonella , La Sorda Rossana , Lattanzio Rossano , Piantelli Mauro , Alberti Saverio
Published: April 2023

Trop-2 proteome profiling.
Data Supplement from A Novel KLF4/LDHA Signaling Pathway Regulates Aerobic Glycolysis in and Progression of Pancreatic Cancer
Authors: Shi Min , Cui Jiujie , Du Jiawei , Wei Daoyan , Jia Zhiliang , Zhang Jun , Zhu Zhenggang , Gao Yong , Xie Keping
Published: April 2023

Table S1. Clinicopathologic characteristics of the patients Represented by the pancreatic TMA specimens; Table S2. The alterations of glycolysis-related genes in GSE21768 Table S3. The alterations of glycolysis-related genes in GSE3113 Table S4. LDHA expression and clinicopathologic characteristics of the pancreatic cancer patients Table S5. LDHB expression and clinicopathologic characteristics of the pancreatic cancer patients Table S6. KLF4 expression and clinicopathologic characteristics of the pancreatic cancer patients
Data Supplement from p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
Authors: Hardwick Nicola R. , Carroll Mary , Kaltcheva Teodora , Qian Dajun , Lim Dean , Leong Lucille , Chu Peiguo , Kim Joseph , Chao Joseph , Fakih Marwan , Yen Yun , Espenschied Jonathan , Ellenhorn Joshua D. I. , Diamond Don J. , Chung Vincent
Published: April 2023

Supplementary Figure 1. Frequency of myeloid derived suppressor cells in the peripheral blood in patients pre and post vaccination with p53MVA
Supplemental Tables 1-4 from Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation
Authors: Yoshida Tatsuya , Ishii Genichiro , Goto Koichi , Neri Shinya , Hashimoto Hiroko , Yoh Kiyotaka , Niho Seiji , Umemura Shigeki , Matsumoto Shingo , Ohmatsu Hironobu , Iida Shinsuke , Niimi Akio , Nagai Kanji , Ohe Yuichiro , Ochiai Atsushi
Published: April 2023

Supplemental Tables 1-4. Supplemental Table 1: Characteristics of primary adenocarcinoma from which CAFs were obtained. Supplemental Table 2: Primary tumor characteristics(N=106). Supplemental Table 3: Impact of predictive factors on progression free survival of EGFR-TKI in patients with EGFR activating mutation by univariate and multivariate analysis (n=106). Supplemental Table 4: The correlation between PDPN expression status and clinical response to EGFR-TKIs in patients with EGFR common mutations, exon 19 deletion and L858R (N=102).
Supplementary Table 1 from Rare Cancer Trial Design: Lessons from FDA Approvals
Authors: Gaddipati Himabindu , Liu Ke , Pariser Anne , Pazdur Richard
Published: April 2023

PDF file, 201KB, Summary of FDA approval data for rare cancer indications from December 1987 to May 2011.
Supplementary Figure Legends from Complete Regression of Metastatic Renal Cell Carcinoma by Multiple Injections of Engineered Mesenchymal Stem Cells Expressing Dodecameric TRAIL and HSV-TK
Authors: Kim Sae Won , Kim Su Jin , Park Sang Hoon , Yang Hyun Gul , Kang Moon Cheol , Choi Young Woo , Kim Seong Muk , Jeun Sin-Soo , Sung Young Chul
Published: April 2023

PDF file - 125K
Suppl Table S1 from Complement Pathway Is Frequently Altered in Endometriosis and Endometriosis-Associated Ovarian Cancer
Authors: Suryawanshi Swati , Huang Xin , Elishaev Esther , Budiu Raluca A. , Zhang Lixin , Kim SungHwan , Donnellan Nicole , Mantia-Smaldone Gina , Ma Tianzhou , Tseng George , Lee Ted , Mansuria Suketu , Edwards Robert P. , Vlad Anda M.
Published: April 2023

Suppl Table S1. Differentially expressed genes from different group comparisons
Data Supplement from Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
Authors: Seiwert Tanguy Y. , Zuo Zhixiang , Keck Michaela K. , Khattri Arun , Pedamallu Chandra S. , Stricker Thomas , Brown Christopher , Pugh Trevor J. , Stojanov Petar , Cho Juok , Lawrence Michael S. , Getz Gad , Brägelmann Johannes , DeBoer Rebecca , Weichselbaum Ralph R. , Langerman Alexander , Portugal Louis , Blair Elizabeth , Stenson Kerstin , Lingen Mark W. , Cohen Ezra E.W. , Vokes Everett E. , White Kevin P. , Hammerman Peter S.
Published: April 2023

Supplementary Figure S3. Overall survival (OS) and progression free survival (PFS) in different subgroups. (A) Subgroup analysis by HPV status and oropharyngeal primary site, (B) subgroup analysis by PIK3CA mutational status and oropharyngeal primary site, and (C) Subgroup analysis by TP53 mutational status and oropharyngeal primary site.
Data Supplement from Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
Authors: Seiwert Tanguy Y. , Zuo Zhixiang , Keck Michaela K. , Khattri Arun , Pedamallu Chandra S. , Stricker Thomas , Brown Christopher , Pugh Trevor J. , Stojanov Petar , Cho Juok , Lawrence Michael S. , Getz Gad , Brägelmann Johannes , DeBoer Rebecca , Weichselbaum Ralph R. , Langerman Alexander , Portugal Louis , Blair Elizabeth , Stenson Kerstin , Lingen Mark W. , Cohen Ezra E.W. , Vokes Everett E. , White Kevin P. , Hammerman Peter S.
Published: April 2023

Supplementary Figure S4. Disruption of various key cellular processes by genomic alterations. Genomic alterations that affect: (A) apoptosis, (B) Differentiation, (C) Oxidative stress and (D) Nucleic acid processing/modification.
Supplementary Figure 2 from Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis
Authors: Chan Christine M. , Jing Xia , Pike Laura A. , Zhou Qiong , Lim Dong-Jun , Sams Sharon B. , Lund Gregory S. , Sharma Vibha , Haugen Bryan R. , Schweppe Rebecca E.
Published: April 2023

PDF file, 107KB, Inhibition of metastasis by post-treatment with dasatinib in an experimental metastasis model.
Supplementary Table S1 from MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival
Authors: Mima Kosuke , Nishihara Reiko , Yang Juhong , Dou Ruoxu , Masugi Yohei , Shi Yan , da Silva Annacarolina , Cao Yin , Song Mingyang , Nowak Jonathan , Gu Mancang , Li Wanwan , Morikawa Teppei , Zhang Xuehong , Wu Kana , Baba Hideo , Giovannucci Edward L. , Meyerhardt Jeffrey A. , Chan Andrew T. , Fuchs Charles S. , Qian Zhi Rong , Ogino Shuji
Published: April 2023

Regular aspirin use after diagnosis and colorectal cancer mortality according to tumor MIR21 expression level among 579 patients with stage I to III colorectal cancer
Supplementary Methods from MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival
Authors: Mima Kosuke , Nishihara Reiko , Yang Juhong , Dou Ruoxu , Masugi Yohei , Shi Yan , da Silva Annacarolina , Cao Yin , Song Mingyang , Nowak Jonathan , Gu Mancang , Li Wanwan , Morikawa Teppei , Zhang Xuehong , Wu Kana , Baba Hideo , Giovannucci Edward L. , Meyerhardt Jeffrey A. , Chan Andrew T. , Fuchs Charles S. , Qian Zhi Rong , Ogino Shuji
Published: April 2023

Assessment of aspirin use and statistical analysis to assess an interaction of tumor MIR21 expression level and regular aspirin use after diagnosis in survival analysis
Supplementary Figure 1 from EWS-FLI-1-Targeted Cytotoxic T-cell Killing of Multiple Tumor Types Belonging to the Ewing Sarcoma Family of Tumors
Authors: Evans Christopher H. , Liu Fangjun , Porter Ryan M. , O'Sullivan Regina P. , Merghoub Taha , Lunsford Elaine P. , Robichaud Kyle , Van Valen Frans , Lessnick Stephen L. , Gebhardt Mark C. , Wells James W.
Published: April 2023

PDF file, 59K, Supplementary Figure S1. A typical example of Bilateral Inguinal Lymph node size 8 days after vaccination with the native peptide QQNPSYDSV (#14) or its modified derivative YLNPSVDSV (#24).
Supplementary Table 1 from Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
Authors: Gavin Patrick G. , Colangelo Linda H. , Fumagalli Debora , Tanaka Noriko , Remillard Matthew Y. , Yothers Greg , Kim Chungyeul , Taniyama Yusuke , Kim Seung Il , Choi Hyun Joo , Blackmon Nicole L. , Lipchik Corey , Petrelli Nicholas J. , O'Connell Michael J. , Wolmark Norman , Paik Soonmyung , Pogue-Geile Kay L.
Published: April 2023

PDF file - 81K, ColoCarta panel
Data Supplement from Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
Authors: Gupta Shiv K. , Mladek Ann C. , Carlson Brett L. , Boakye-Agyeman Felix , Bakken Katrina K. , Kizilbash Sani H. , Schroeder Mark A. , Reid Joel , Sarkaria Jann N.
Published: April 2023

Supplementary Figure S2. Veliparib mediated enhancement of TMZ induced apoptosis in GBM cells
Supplemental Figures S1-S17 from Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression
Authors: Chang Te-Sheng , Wu Yu-Chih , Chi Ching-Chi , Su Wei-Chi , Chang Pey-Jium , Lee Kam-Fai , Tung Tao-Hsin , Wang Jui , Liu Jun-Jen , Tung Shui-Yi , Kuo Liang-Mou , Ho Hong-Nerng , Ling Thai-Yen , Huang Yen-Hua
Published: April 2023

Supplemental Figures S1-S17. Figure S1. The CONSORT diagram showing the disposition of patients through each stage of the study. Figure S2. Correlation of the expressions of OCT4 and NANOG with IGF-IR in human HCC. Figure S3. Correlation of the expressions of OCT4, NANOG, and IGF-IR with the early recurrence of human HCC. Figure S4. Correlation of the expressions of OCT4, NANOG, and IGF-IR with the overall survival (OS) of human HCC. Figure S5. Correlation of the expressions of OCT4, NANOG, and IGF-IR with the "Time-to-recurrence" of human HCC. Figure S6. Training and Validation mode. Figure S7. IGF-I stimulate the expressions of OCT4 and NANOG in human HBV-HCC cell lines. Figure S8. IGF-I/IGF-IR signaling regulates stemness expression in human HBV+HBsAg+ HepG2.2.15 cells. Figure S9. Flow cytometry analysis. Figure S10. The effect of IL-6 on IGF-IR, OCT4, and NANOG expressions in human HBV-HCC cells. Figure S11. Coomassie blue staining of the SDS-PAGE gels showed the levels of secreted IGF-I, OCT4, and NANOG proteins in the conditioned medium from IL-6-treated Hep3B cells. Figure S12. Effects of shIGF-IR on IL-6-induced tumor secondary sphere formation. Figure S13. IL-6 increases stemness properties through IGF-IR activation in human HBV+HBsAg+ HepG2.2.15 cells. Figure S14. Flow cytometry analysis. Figure S15. Tumor sizes of xenografted Hep3B cells in athymic nude mice. Figure S16. Effect of IL-6 on the transactivation of IGF-IR/AKT signaling in HBV-HCC cell line. Figure S17. Positive correlation between OCT4 and NANOG protein levels and IGF-IR phosphorylation in human HCC tissues.
Supplementary Figure 1 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma
Authors: Radon Tomasz P. , Massat Nathalie J. , Jones Richard , Alrawashdeh Wasfi , Dumartin Laurent , Ennis Darren , Duffy Stephen W. , Kocher Hemant M. , Pereira Stephen P. , Guarner (posthumous) Luisa , Murta-Nascimento Cristiane , Real Francisco X. , Malats Núria , Neoptolemos John , Costello Eithne , Greenhalf William , Lemoine Nick R. , Crnogorac-Jurcevic Tatjana
Published: April 2023

Urine proteome analysis. A, schematic outline of the study. B, classification of total identified proteins according to sub-cellular localisation and C, functional activity determined by Ingenuity Pathway Analysis. H: healthy, CP: chronic pancreatitis, PDAC: pancreatic ductal adenocarcinoma, GeLC/MS/MS: SDS-PAGE-Liquid Chromatography-Tandem Mass Spectrometry.
Supplementary Table 1 from Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries
Authors: Ok Chi Young , Li Ling , Xu-Monette Zijun Y. , Visco Carlo , Tzankov Alexander , Manyam Ganiraju C. , Montes-Moreno Santiago , Dybaer Karen , Chiu April , Orazi Attilio , Zu Youli , Bhagat Govind , Chen Jiayu , Richards Kristy L. , Hsi Eric D. , Choi William W. L. , van Krieken J. Han , Huh Jooryung , Ai Weiyun , Ponzoni Maurilio , Ferreri Andrés J.M. , Farnen John P. , Møller Michael B. , Bueso-Ramos Carlo E. , Miranda Roberto N. , Winter Jane N. , Piris Miguel A. , Medeiros L. Jeffrey , Young Ken H.
Published: April 2023

PDF file - 57KB, Supplemental Table 1. Genes differently expressed in EBV+ DLBCL vs. EBV-negative DLBCL. A. Genes upregulated in EBV+ DLBCL; B. Genes downregulated in EBV+ DLBCL
Supplementary Table 2 from Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors
Authors: Endo Makoto , Yamamoto Hidetaka , Setsu Nokitaka , Kohashi Kenichi , Takahashi Yusuke , Ishii Takeaki , Iida Kei-ichiro , Matsumoto Yoshihiro , Hakozaki Michiyuki , Aoki Mikiko , Iwasaki Hiroshi , Dobashi Yoh , Nishiyama Kenichi , Iwamoto Yukihide , Oda Yoshinao
Published: April 2023

XLSX file - 9K, Multiivariate analysis for overall survival with p-AKT expression
Supplementary Movie from Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo
Authors: Dibra Denada , Mitra Abhisek , Newman Melisa , Xia Xueqing , Cutrera Jeffry J. , Gagea Mihai , Kleinerman Eugenie S. , Lozano Guillermina , Li Shulin
Published: April 2023

Supplementary Video: Video portraying rear leg paresis in IL27RA-/- p53R172H/+ mice.
Supplementary Figure Legends from Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo
Authors: Dibra Denada , Mitra Abhisek , Newman Melisa , Xia Xueqing , Cutrera Jeffry J. , Gagea Mihai , Kleinerman Eugenie S. , Lozano Guillermina , Li Shulin
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 1 from SIRT6 Overexpression Potentiates Apoptosis Evasion in Hepatocellular Carcinoma via BCL2-Associated X Protein–Dependent Apoptotic Pathway
Authors: Ran Long-Kuan , Chen Yong , Zhang Zhen-Zhen , Tao Na-Na , Ren Ji-Hua , Zhou Li , Tang Hua , Chen Xiang , Chen Ke , Li Wan-Yu , Huang Ai-Long , Chen Juan
Published: April 2023

Western blot analysis of SIRT6 in 53 paired HCC tissues (T) and adjacent non-tumor liver tissues (N). β-actin was used as a loading control.
Supplementary Table 1 and Figure legend for Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Ma Cynthia X. , Sanchez Cesar , Gao Feng , Crowder Robert , Naughton Michael , Pluard Timothy , Creekmore Allison , Guo Zhanfang , Hoog Jeremy , Lockhart A. Craig , Doyle Austin , Erlichman Charles , Ellis Matthew J.
Published: April 2023

Supplementary Table 1 shows the clinical benefit rate and time to progression in subgroups divided according to treatment setting when enrolled on the trial and the trial regimens received.
Supplementary Data from Calreticulin Promotes Migration and Invasion of Esophageal Cancer Cells by Upregulating Neuropilin-1 Expression via STAT5A
Authors: Shi Feng , Shang Li , Pan Bei-Qing , Wang Xiao-Min , Jiang Yan-Yi , Hao Jia-Jie , Zhang Yu , Cai Yan , Xu Xin , Zhan Qi-Min , Wang Ming-Rong
Published: April 2023

Supplementary Data. Supplementary Materials and Methods, Supplementary Figure Legends
Supplemental Table 3 from A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Authors: Reiss Kim A. , Herman Joseph M. , Zahurak Marianna , Brade Anthony , Dawson Laura A. , Scardina Angela , Joffe Caitlin , Petito Emily , Hacker-Prietz Amy , Kinders Robert J. , Wang Lihua , Chen Alice , Temkin Sarah , Horiba Naomi , Siu Lillian L. , Azad Nilofer S.
Published: April 2023

Quality of life (QoL) t-tests for all patients (A), GYN versus non-GYN patients (B) and patients who completed cycle 2 and those who did not (C).
Supplemental Figure 1 from A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
Authors: Reiss Kim A. , Herman Joseph M. , Zahurak Marianna , Brade Anthony , Dawson Laura A. , Scardina Angela , Joffe Caitlin , Petito Emily , Hacker-Prietz Amy , Kinders Robert J. , Wang Lihua , Chen Alice , Temkin Sarah , Horiba Naomi , Siu Lillian L. , Azad Nilofer S.
Published: April 2023

CTC number and ɣ-H2AX-positive CTC changes during treatment with radiotherapy and veliparib.
Supplementary Figure S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Authors: Scaltriti Maurizio , Nuciforo Paolo , Bradbury Ian , Sperinde Jeff , Agbor-Tarh Dominique , Campbell Christine , Chenna Ahmed , Winslow John , Serra Violeta , Parra Josep Lluis , Prudkin Ludmila , Jimenez José , Aura Claudia , Harbeck Nadia , Pusztai Lajos , Ellis Catherine , Eidtmann Holger , Arribas Joaquin , Cortes Javier , de Azambuja Evandro , Piccart Martine , Baselga José
Published: April 2023

Supplementary Figure S1. Distribution of HER2 expression (measured by HERmark) in all patients (left) and in 3+ IHC cohort patients (right). All patient: n=324; IHC3+: n=232.
Data Supplement from Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
Authors: Tsimberidou Apostolia-Maria , Wen Sijin , Hong David S. , Wheler Jennifer J. , Falchook Gerald S. , Fu Siqing , Piha-Paul Sarina , Naing Aung , Janku Filip , Aldape Kenneth , Ye Yang , Kurzrock Razelle , Berry Donald
Published: April 2023

Supplemental Table 1. Distribution of Molecular Alterations by Diagnosis (I)
Supplementary figure 3 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy
Authors: Feng Liang , Yao Hang-Ping , Wang Wei , Zhou Yong-Qing , Zhou Jianwei , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

Supplementary figure 3. Effect of Zt/g4-DM1 on reduction of cell viability in CRC cell lines expressing different numbers of RON receptor
Data Supplement from Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
Authors: Tsimberidou Apostolia-Maria , Wen Sijin , Hong David S. , Wheler Jennifer J. , Falchook Gerald S. , Fu Siqing , Piha-Paul Sarina , Naing Aung , Janku Filip , Aldape Kenneth , Ye Yang , Kurzrock Razelle , Berry Donald
Published: April 2023

Supplemental Table 2. Distribution of Molecular Alterations by Diagnosis (II)
Data Supplement from Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
Authors: Tsimberidou Apostolia-Maria , Wen Sijin , Hong David S. , Wheler Jennifer J. , Falchook Gerald S. , Fu Siqing , Piha-Paul Sarina , Naing Aung , Janku Filip , Aldape Kenneth , Ye Yang , Kurzrock Razelle , Berry Donald
Published: April 2023

Supplemental Table 4. Patient characteristics: tumor types by type of therapy
Supplementary Table 1 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy
Authors: Feng Liang , Yao Hang-Ping , Wang Wei , Zhou Yong-Qing , Zhou Jianwei , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

Supplementary Table 1. Biochemical and biological features of anti-RON mAbs Zt/g4
Legends for supplementary figures from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy
Authors: Feng Liang , Yao Hang-Ping , Wang Wei , Zhou Yong-Qing , Zhou Jianwei , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

Legends for supplementary figures
Supplementary Tables 1 - 6 from Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
Authors: Jahangiri Arman , De Lay Michael , Miller Liane M. , Carbonell W. Shawn , Hu Yu-Long , Lu Kan , Tom Maxwell W. , Paquette Jesse , Tokuyasu Taku A. , Tsao Sean , Marshall Roxanne , Perry Arie , Bjorgan Kirsten M. , Chaumeil Myriam M. , Ronen Sabrina M. , Bergers Gabriele , Aghi Manish K.
Published: April 2023

PDF file - 1353K, Supplementary Table S1. Patient and tumor characteristics from the 22 bevacizumab-resistant versus 22 bevacizumab-na�ve glioblastomas from whom paired pre-treatment tissue was available. Supplementary Table S2. Altered transcripts in 15 bevacizumab-resistant glioblastomas compared to before treatment. Supplementary Table S3. Altered transcripts in 15 bevacizumab-resistant glioblastomas compared to before treatment. Supplementary Table S4. Altered transcripts in bevacizumab-naive recurrent glioblastomas compared to their paired glioblastomas at diagnosis. Supplemetary Table S5. FISH Results. Supplementary Table S6. Patient and tumor characteristics from 22 bevacizumab-na�ve recurrent glioblastomas (control group) from whom paired pre-treatment tissue was available.
Supplementary Table 1 from Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention
Authors: Hildebrandt Michelle A.T. , Lippman Scott M. , Etzel Carol J. , Kim Edward , Lee J. Jack , Khuri Fadlo R. , Spitz Margaret R. , Lotan Reuben , Hong Waun Ki , Wu Xifeng
Published: April 2023

PDF file, 63KB, Minor allele frequencies (MAF), genotype counts, and results in the 13-cRA treatment arm.
Supplementary Table S1 from The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
Authors: Krepler Clemens , Chunduru Srinivas K. , Halloran Molly B. , He Xu , Xiao Min , Vultur Adina , Villanueva Jessie , Mitsuuchi Yasuhiro , Neiman Eric M. , Benetatos Christopher , Nathanson Katherine L. , Amaravadi Ravi K. , Pehamberger Hubert , McKinlay Mark , Herlyn Meenhard
Published: April 2023

PDF file - 57 KB, Mutation profile of cell lines treated with birinapant.
Supplementary Figure Legend from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Authors: Fabre Claire , Mimura Naoya , Bobb Kathryn , Kong Sun-Young , Gorgun Güllü , Cirstea Diana , Hu Yiguo , Minami Jiro , Ohguchi Hiroto , Zhang Jie , Meshulam Jeffrey , Carrasco Ruben D. , Tai Yu-Tzu , Richardson Paul G. , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

PDF file, 26K.
Figure-S6 from AMACR Amplification in Myxofibrosarcomas: A Mechanism of Overexpression That Promotes Cell Proliferation with Therapeutic Relevance
Authors: Li Chien-Feng , Fang Fu-Min , Lan Jui , Wang Jun-Wen , Kung Hsing-Jien , Chen Li-Tzong , Chen Tzu-Ju , Li Shau-Hsuan , Wang Yu-Hui , Tai Hui-Chun , Yu Shih-Chen , Huang Hsuan-Ying
Published: April 2023

Figure-S6 The in vitro (A) and in vivo (B) downregulating effects of EO treatment on cyclin T2, cyclin D1, and Ki-67 levels. (A): In both NMFH-1 and NMFH-2 myxofibrosarcoma cell lines, western blots (left) reveal reduced expression levels of cyclin T2, cyclin D1, and Ki-67 cell cycle regulatory proteins in cells treated with EO at 40 uM, which, as illustrated in the corresponding histograms (right), are statistically significant in triplicate experiments compared to the control groups. (B) The comparison of immunohistochemical results between EO-treated (right) and control (left) NMFH-2 xenograft specimens shows significantly lower nuclear labeling indices of cyclin T2, cyclin D1, and Ki-67.
Supplemental Fig S1 and S2 from RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma
Authors: Mi Shijun , Lin Mingyan , Brouwer-Visser Jurriaan , Heim Jennifer , Smotkin David , Hebert Tiffany , Gunter Marc J. , Goldberg Gary L. , Zheng Deyou , Huang Gloria S.
Published: April 2023

Figure S1. Correlation of RACGAP1 Immunohistochemical Staining and mRNA Expression; Figure S2. Survivin Expression in CS99 Treated With YM155
Data Supplement from Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma
Authors: Trabucco Sally E. , Gerstein Rachel M. , Evens Andrew M. , Bradner James E. , Shultz Leonard D. , Greiner Dale L. , Zhang Hong
Published: April 2023

Supplementary Figure Legend
Suppl Table S6 from RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma
Authors: Mi Shijun , Lin Mingyan , Brouwer-Visser Jurriaan , Heim Jennifer , Smotkin David , Hebert Tiffany , Gunter Marc J. , Goldberg Gary L. , Zheng Deyou , Huang Gloria S.
Published: April 2023

Table S6. Primer Sequences for Real-Time PCR.
Supplementary Information from Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Authors: Sharkey Robert M. , McBride William J. , Cardillo Thomas M. , Govindan Serengulam V. , Wang Yang , Rossi Edmund A. , Chang Chien-Hsing , Goldenberg David M.
Published: April 2023

Supplementary sections, including additional Materials and Methods, as well as Results and Tables. Table S1. SN-38 and SN-38G standard curves using triplicate dilutions of each concentration with single HPLC run. Table S2. SN-38 extraction efficiency. Table S3. Area under the curve (AUC) analysis of various products in the serum of nude mice given irinotecan or IMMU-132. Table S4. In vitro glucuronidation assay. Table S5. Analysis of products in the large intestine of animals given irinotecan or IMMU-132 (Study 2). Values represent the mean {plus minus} SD (N = 3) and are expressed in µg.
Supplementary Figure S3 from Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Authors: Sharkey Robert M. , McBride William J. , Cardillo Thomas M. , Govindan Serengulam V. , Wang Yang , Rossi Edmund A. , Chang Chien-Hsing , Goldenberg David M.
Published: April 2023

Concentrations of constitutive products in the serum from animals given irinotecan or IMMU-132 in nude mice bearing Capan-1 from 2 separate studies.
Supplementary Table S3B from Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
Authors: Somlo George , Atzori Francesco , Strauss Lewis C. , Geese William J. , Specht Jennifer M. , Gradishar William J. , Rybicki Alissa , Sy Oumar , Vahdat Linda T. , Cortes Javier
Published: April 2023

PDF file - 25 KB, Table S3B Changes in biomarker values after 3 and 6 weeks of dasatinib and capecitabine
Supplementary Figure 1 from Ectopic Expression of Cancer–Testis Antigens in Cutaneous T-cell Lymphoma Patients
Authors: Litvinov Ivan V. , Cordeiro Brendan , Huang Yuanshen , Zargham Hanieh , Pehr Kevin , Doré Marc-André , Gilbert Martin , Zhou Youwen , Kupper Thomas S. , Sasseville Denis
Published: April 2023

PDF file - 324KB, Detailed description of RT-PCR analysis of CT genes expression in CTCL patients.
Supplementary Methods and Figure Legends from LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
Authors: Liu Ling , Zeng Wei , Wortinger Mark A. , Yan S. Betty , Cornwell Paul , Peek Victoria L. , Stephens Jennifer R. , Tetreault Jonathan W. , Xia Jinqi , Manro Jason R. , Credille Kelly M. , Ballard Darryl W. , Brown-Augsburger Patricia , Wacheck Volker , Chow Chi-Kin , Huang Lihua , Wang Yong , Denning Irene , Davies Julian , Tang Ying , Vaillancourt Peter , Lu Jirong
Published: April 2023

Supplementary Methods and Supplementary Figure Legends
Supplementary Figures from LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
Authors: Liu Ling , Zeng Wei , Wortinger Mark A. , Yan S. Betty , Cornwell Paul , Peek Victoria L. , Stephens Jennifer R. , Tetreault Jonathan W. , Xia Jinqi , Manro Jason R. , Credille Kelly M. , Ballard Darryl W. , Brown-Augsburger Patricia , Wacheck Volker , Chow Chi-Kin , Huang Lihua , Wang Yong , Denning Irene , Davies Julian , Tang Ying , Vaillancourt Peter , Lu Jirong
Published: April 2023

Supplementary Figures. Figure S1. Binding of LY2875358 to human and cynomolgus monkey MET-ECD and the blocking of HGF binding to MET-ECD by LY2875358 as determined by Biacore and ELISA assays Figure S2: Binding epitope regions of LY2875358 determined by H/D mass spectrometry were shown on the crystal structure of ternary complex MET-Sema-PSI with onartuzumab and HGFÃŽÂ² Figure S3. Effect of LY2875358 on HGF-induced cell migration compared to huOA-5D5. Figure S4. Effect of LY2875358 on pan-AKT phosphorylation in Caki-1, H441, and HepG2 cells. Figure S5. Effect of LY2875358 on Caki-1 cell proliferation. Figure S6. Effect of LY2875358 on HepG2 tubulogenesis. Figure S7. Effect of LY2875358 on staurosporin (STS) induced cell apoptosis. Figure S8. Effect of lysosome inhibitor leupeptin on LY2875358-induced MET localization to the lysosome. Figure S9. Effect of LY2875358 and Fab fragment of LY2875358 on HGF binding to MET, depletion of cell surface MET, and proliferation of MET amplified cell lines.
Supplementary Table 2 from A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Authors: Pal Sumanta , Azad Arun , Bhatia Shailender , Drabkin Harry , Costello Brian , Sarantopoulos John , Kanesvaran Ravindran , Lauer Richard , Starodub Alexander , Hauke Ralph , Sweeney Christopher J. , Hahn Noah M. , Sonpavde Guru , Richey Stephen , Breen Timothy , Kremmidiotis Gabriel , Leske Annabell , Doolin Elizabeth , Bibby David C. , Simpson Jeremy , Iglesias Jose , Hutson Thomas
Published: April 2023

Supplementary Table 2. Drug-related treatment emergent adverse events by CTCAE grade ({greater than or equal to} Grade 2) seen in the phase I component of the study.
Supplementary Figure S1 from T-Cell Levels Are Prognostic in Mantle Cell Lymphoma
Authors: Nygren Lina , Wasik Agata M. , Baumgartner-Wennerholm Stefanie , Jeppsson-Ahlberg Åsa , Klimkowska Monika , Andersson Patrik , Buhrkuhl Daren , Christensson Birger , Kimby Eva , Wahlin Björn E. , Sander Birgitta
Published: April 2023

Supplementary Figure S1. Lymphoma cells are visualized by immunohistochemical staining for Cyclin D1. A. Mantle zone subtype is characterized by expanded mantle zones consisting of lymphoma cells which surround preserved germinal centers. B. Nodular subtype C. Diffuse subtype.
Data Supplement from Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR–Based Platform
Authors: Guo Wei , Yang Xin-Rong , Sun Yun-Fan , Shen Min-Na , Ma Xiao-Lu , Wu Jiong , Zhang Chun-Yan , Zhou Yan , Xu Yang , Hu Bo , Zhang Xin , Zhou Jian , Fan Jia
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
Authors: Filipazzi Paola , Pilla Lorenzo , Mariani Luigi , Patuzzo Roberto , Castelli Chiara , Camisaschi Chiara , Maurichi Andrea , Cova Agata , Rigamonti Gianluigi , Giardino Felicetta , Di Florio Annabella , Asioli Marco , Frati Paola , Sovena Gloria , Squarcina Paola , Maio Michele , Danielli Riccardo , Chiarion-Sileni Vanna , Villa Antonello , Lombardo Claudia , Tragni Gabrina , Santinami Mario , Parmiani Giorgio , Rivoltini Licia
Published: April 2023

PDF file - 54K, Flow diagram for phase II randomized trial of adjuvanted multipeptide vaccination
Supplemental Table 3 from The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB
Authors: Deng Changchun , Lipstein Mark , Rodriguez Richard , Serrano Xavier O. Jirau , McIntosh Christine , Tsai Wei-Yann , Wasmuth Andrew S. , Jaken Susan , O'Connor Owen A.
Published: April 2023

Supplemental Table 3. Interaction of LY2409881 with other drugs/compounds in two DLBCL cell line.
Supplementary Table 1 from Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis
Authors: Dal Molin Marco , Zhang Ming , de Wilde Roeland F. , Ottenhof Niki A. , Rezaee Neda , Wolfgang Christopher L. , Blackford Amanda , Vogelstein Bert , Kinzler Kenneth W. , Papadopoulos Nickolas , Hruban Ralph H. , Maitra Anirban , Wood Laura D.
Published: April 2023

Supplementary Table 1. Summary of exome sequencing data for VLTSs
Supplemental Figures S4-S7 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients
Authors: Guo Yuna , Kenney S. Ray , Cook Linda , Adams Sarah F. , Rutledge Teresa , Romero Elsa , Oprea Tudor I. , Sklar Larry A. , Bedrick Edward , Wiggins Charles L. , Kang Huining , Lomo Lesley , Muller Carolyn Y. , Wandinger-Ness Angela , Hudson Laurie G.
Published: April 2023

Supplemental Figures S4-S7. Supplemental Figure S4 - Survival estimates based on Cox-regression for Stage I (AJCC) with completion of chemotherapy. Supplemental Figure S5 - Survival estimates based on Cox-regression for Stage II (AJCC) with completion of chemotherapy. Supplemental Figure S6 - Survival estimates based on Cox-regression for Stage III (AJCC) with completion of chemotherapy. Supplemental Figure S7 - Survival estimates based on Cox-regression for Stage IV (AJCC) with completion of chemotherapy.
Supplementary table 2 from A Promyelocytic Leukemia Protein–Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma
Authors: Dvorkina Maria , Nieddu Valentina , Chakelam Shalini , Pezzolo Annalisa , Cantilena Sandra , Leite Ana Paula , Chayka Olesya , Regad Tarik , Pistorio Angela , Sementa Angela Rita , Virasami Alex , Barton Jack , Montano Ximena , Lechertier Tanguy , Brindle Nicola , Morgenstern Daniel , Lebras Morgane , Burns Alan J. , Saunders Nigel J. , Hodivala-Dilke Kairbaan , Bagella Luigi , De The Hugues , Anderson John , Sebire Neil , Pistoia Vito , Sala Arturo , Salomoni Paolo
Published: April 2023

New neuroblastoma patient cohort
Supplementary Methods, Supplementary Tables 1-2 from Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome
Authors: Caliò Anna , Zamò Alberto , Ponzoni Maurilio , Zanolin Maria Elisabetta , Ferreri Andrés J.M. , Pedron Serena , Montagna Licia , Parolini Claudia , Fraifeld Vadim E. , Wolfson Marina , Yanai Hagai , Pizzolo Giovanni , Doglioni Claudio , Vinante Fabrizio , Chilosi Marco
Published: April 2023

Table S1. Multivariate analysis for event occurrence in 132/147* patients. Table S2. Probability of EFS (95%CI) according sCD30 and p16INK4a/p21CIP1/WAF1 expression at diagnosis.
Supplementary Table S3 from Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer
Authors: Koido Shigeo , Homma Sadamu , Okamoto Masato , Takakura Kazuki , Mori Masako , Yoshizaki Shinji , Tsukinaga Shintaro , Odahara Shunichi , Koyama Seita , Imazu Hiroo , Uchiyama Kan , Kajihara Mikio , Arakawa Hiroshi , Misawa Takeyuki , Toyama Yoichi , Yanagisawa Satoru , Ikegami Masahiro , Kan Shin , Hayashi Kazumi , Komita Hideo , Kamata Yuko , Ito Masaki , Ishidao Takefumi , Yusa Sei-ichi , Shimodaira Shigetaka , Gong Jianlin , Sugiyama Haruo , Ohkusa Toshifumi , Tajiri Hisao
Published: April 2023

Maximum of IFN-γ positive cells in CD4 or CD8 T cells by vaccinations.
Supplementary Figure 1 from Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome
Authors: Caliò Anna , Zamò Alberto , Ponzoni Maurilio , Zanolin Maria Elisabetta , Ferreri Andrés J.M. , Pedron Serena , Montagna Licia , Parolini Claudia , Fraifeld Vadim E. , Wolfson Marina , Yanai Hagai , Pizzolo Giovanni , Doglioni Claudio , Vinante Fabrizio , Chilosi Marco
Published: April 2023

Prognostic significance of the combined variable p16INK4a/p21CIP1/WAF1 in patients with cHL.
Supplementary Figure S2 from Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer
Authors: Koido Shigeo , Homma Sadamu , Okamoto Masato , Takakura Kazuki , Mori Masako , Yoshizaki Shinji , Tsukinaga Shintaro , Odahara Shunichi , Koyama Seita , Imazu Hiroo , Uchiyama Kan , Kajihara Mikio , Arakawa Hiroshi , Misawa Takeyuki , Toyama Yoichi , Yanagisawa Satoru , Ikegami Masahiro , Kan Shin , Hayashi Kazumi , Komita Hideo , Kamata Yuko , Ito Masaki , Ishidao Takefumi , Yusa Sei-ichi , Shimodaira Shigetaka , Gong Jianlin , Sugiyama Haruo , Ohkusa Toshifumi , Tajiri Hisao
Published: April 2023

Treatment schedule.
Supplemental Figure 1 from First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
Authors: Rodon Jordi , Carducci Michael A. , Sepulveda-Sánchez Juan M , Azaro Analia , Calvo Emiliano , Seoane Joan , Braña Irene , Sicart Elisabet , Gueorguieva Ivelina , Cleverly Ann L. , Pillay N. Sokalingum , Desaiah Durisala , Estrem Shawn T. , Paz-Ares Luis , Holdhoff Matthias , Blakeley Jaishri , Lahn Michael M. , Baselga Jose
Published: April 2023

Supplemental Figure 1. Platelet recovery after lomustine administration was not diminished by giving LY2157299 during the recovery period suggesting no bone marrow toxicity.
Legend for Supplementary Figure 1 from First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
Authors: Rodon Jordi , Carducci Michael A. , Sepulveda-Sánchez Juan M , Azaro Analia , Calvo Emiliano , Seoane Joan , Braña Irene , Sicart Elisabet , Gueorguieva Ivelina , Cleverly Ann L. , Pillay N. Sokalingum , Desaiah Durisala , Estrem Shawn T. , Paz-Ares Luis , Holdhoff Matthias , Blakeley Jaishri , Lahn Michael M. , Baselga Jose
Published: April 2023

Legend for Supplementary Figure 1
Supplementary Figures 1 - 3, Tables 1 - 2 from Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
Authors: Higgins Brian , Glenn Kelli , Walz Antje , Tovar Christian , Filipovic Zoran , Hussain Sazzad , Lee Edmund , Kolinsky Kenneth , Tannu Shahid , Adames Violeta , Garrido Rosario , Linn Michael , Meille Christophe , Heimbrook David , Vassilev Lyubomir , Packman Kathryn
Published: April 2023

PDF file - 311KB, Table S1. Results of proliferation assay. Table S2. Estimated PKPD population parameters. Fig. S1. Schematic view of the PK/PD model. Fig S2. Observed PK parameter and model predicted. Fig S3. Visual predictive check.
Supplementary Methods, Table 1 from Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model
Authors: Sun Zhi-Jun , Zhang Lu , Hall Bradford , Bian Yansong , Gutkind J. Silvio , Kulkarni Ashok B.
Published: April 2023

PDF file - 104K, Chemicals and Reagents, Histology and Immunostaining, Western blot analysis and siRNA source. Supplementary References
Supplementary Figure 1 from Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model
Authors: Sun Zhi-Jun , Zhang Lu , Hall Bradford , Bian Yansong , Gutkind J. Silvio , Kulkarni Ashok B.
Published: April 2023

PDF file - 114K, Increase survivin levels in HNSCC cell lines treated with siRNA for TGFbr1 and Pten, and activation of PI3K, Akt, mTOR and survivin in Tgfbr1/Pten 2cKO mouse HNSCC